The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

A bespoke CRISPR base-editing therapy designed for a single infant with CPS1 deficiency has produced encouraging early ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Genetic engineering is moving from the lab bench into clinics, farms, and even family planning decisions, promising to change ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible ...

A collaborative study led by biomedical researchers Chris Lengner and M. Andrés Blanco at the School of Veterinary Medicine at the University of Pennsylvania has identified two genes that suppress ...